报价延迟最少15分钟:2025/08/13 05:23 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.48
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-24.80/-5.85
|
|
企业价值
19.16M
|
| 资产负债 |
|
每股账面净值
-3.37
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.57M
|
|
每股收益
1.50
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/08/13 05:23 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. |
